SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing sovereign-AI demand and growth in customized software, is reinforcing Palantirs AI growth story as the stock reaches fresh highs. Bulls are celebrating the breakout and speculating about a short squeeze, while skeptics warn that the valuation is stretched and the rally could pull back.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile shares sold off sharply after SpaceX agreed to acquire low-band spectrum for Starlink Mobile, raising fears that it could eventually compete with established wireless carriers. Traders are divided between seeing a lasting competitive threat and viewing the reaction as excessive, arguing that building a capable terrestrial network would take substantial time and investment.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally is drawing attention to Starknets privacy and Bitcoin DeFi push, including strkBTC and STRK20, alongside its post-quantum security narrative. Traders are largely bullish on the technology and momentum, while some remain wary of token unlocks and selling pressure.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canada is drawing attention after a sharp selloff and continued underperformance versus U.S. airlines. Traders debate whether lingering share supply after the substantial issuer bid, short selling and delayed buybacks are adding pressure; concerns about oil and jet-fuel costs contrast with bullish hopes that buybacks will support a rebound.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

A report of a planned NIH-backed push to accelerate personalized cancer vaccines has lifted vaccine stocks, including BioNTech. Traders are discussing the sector rally and BioNTechs oncology pipeline, while some question why BNTX is lagging Moderna.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

DOTs sharp rebound from recent lows is drawing attention, though traders note there was no clear announcement behind the move. Bulls point to Polkadot upgrades, tokenomics changes and the proposed dotUSD stablecoin, while skeptics view the bounce as temporary amid concerns about weak demand and the long downtrend.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is drawing attention for choppy, range-bound trading, with repeated failures to clear the psychologically important 10-cent level fueling frustration. Bulls are calling the pullbacks accumulation opportunities and anticipating a breakout alongside a broader crypto rally, while bears see the stalled price action as a sign of further weakness.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

SpaceXs agreement to acquire Grain Managements low-band spectrum has intensified concerns that it could compete more directly with AST SpaceMobile, contributing to a sharp selloff. Traders are divided: some see the deal as a threat, while others argue ASTSs carrier partnerships and access to operators spectrum could strengthen its role as a neutral satellite partner; launch execution and delays also remain concerns.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

ADAs rebound has traders watching for a breakout, with bullish posters pointing to rising volume, technical signals and short-squeeze potential. Some cite Cardanos Mastercard partnership and other adoption developments as support, while skeptics question whether the news will drive real usage and warn the move could fade.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

Golds recent pullback and tentative rebound are driving discussion, with traders weighing whether support marks a bottom or whether a stronger dollar, elevated yields and hawkish Fed expectations could extend the decline. Some see dip-buying and central-bank demand as supportive, while others remain cautious pending confirmation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Exelixis (EXEL) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?

Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?

Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Exelixis (EXEL) is a Strong Growth Stock

EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term

Equity

The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread. 

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.read more...

Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$EXEL this request doesn’t affect the approval of the drug it generally speaking it just extends the breath of the label for the drug
It’s not a negative it’s actually a positive it’s gonna lead to an approval with extending the breath of the label based upon side effects

Jimmy Lithgow

$EXEL big time rug pull underway. Big boys ran it up till noon today to unload shares. Big sell off. Not sure if news just hit or or whether it’s just algos. Hard for breakouts to work however with the changing policies minute by minute by this admin every day. Hopefully this admin will stop being so volatile so the stock market can stop being so volatile. They go hand in hand.

Chris

EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term

$EXEL $IJH $VTI

https://stocktwits.com/news/equity/markets/exel-stock-slides-after-fda-adds-three-months-to-cancer-drug-review-william-blair-sees-more-swings-in-near-term/cZtXM0eRBbg

Stocktwits News

$EXEL Exelixis says FDA extends review period for zanzalintinib NDA by three months 
 
Exelixis announced that on September 10, the U.S. Food and Drug Administration notified Exelixis that it had extended the review period for Exelixis' new drug application for zanzalintinib, in combination with atezolizumab, for the treatment of patients with metastatic colorectal cancer by three months. In response to an FDA information request, Exelixis had submitted updated safety and efficacy data, which the FDA has deemed a major amendment. The updated Prescription Drug User Fee Act action date is March 3, 2027.

Feed

News

Sentiment

Earnings

Fundamentals

Info

EXEL Exelixis Inc

Fundamentals

Latest EXEL News